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TRANSDERMAL NITROGLYCERINE VERSUS ORAL NIFEDIPINE 
ADMINISTRATION FOR TOCOLYSIS IN PRETERM LABOUR 
 
ABSTRACT  
Objective  
Comparison of oral nifedipine and transdermal nitroglycerin for tocolysis  in 
preterm labour in the following effects, acute tocolytic  effect, duration of prolongation of 
pregnancy , neonatal outcome. 
Materials and methods  
Study on tocolysis in preterm labour was conducted in Government Rajaji 
Hospital from December 2010 to November 2011. 100 women with preterm labour 
randomly selected from the pregnant women attending  antenatal OP and from labour 
ward from the department of obstetrics and gynecology. Out of which 50 women were 
recruited for oral nifedipine ( initially 20mg , followed by 10mg till the contractions stop)  
and another 50 women were recruited for transdermal  nitroglycerin patch (25 mg, 
directly applied over the skin of the abdomen).  
Inclusion criteria :  
Woman with singleton pregnancy with preterm labour from 28 – 36 weeks of 
gestation were selected for this study.    
Exclusion criteria:  
Pregnant women with preterm labour with premature  rupture of membranes, fetal 
distress , major fetal congenital anomalies , chorioamnionitis antepartum hemorrhage , 
sensitivity or  contra indication to nifedipine/nitrates,  were excluded from this study .  
Results  
In both the groups time needed for tocolysis ranged from 2-12  hours . Mean time 
needed for tocolysis in group I was  4.55 hours and with group II , it was 6.09 hours . 
when acute tocolytic effect  ( Prolongation of pregnancy beyond 48 hours )  was 
considered , it was 45 women  in group I and 36 women in group II.  Mean duration of 
Prolongation of pregnancy with group I was 20.74  days and with group II , it was 13.5 
days . In group I 7 babies got admitted in new born ward , 16 babies in group II got 
admitted in new born ward .           
Conclusion  
When compared with nitroglycerin , nifedipine is found  to be safe and successful 
in achieving  complete tocolysis  and also effective in prolongation of pregnancy . 
Nifedipine has minimal maternal side effects and better neonatal outcome.     
  Key word  
Preterm labour , Oral nifedipine , glyceryltrinitrate  transdermal patch  
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INTRODUCTION  
 
The World health organization has estimated that 12.9. million 
births (or) 9.6% of all births world wide, were preterm in 2005. 
In the era of modern obstetrics, despite advancement in all 
specialities, the delivery of infants in preterm period of gestation is a 
major factor contributing to perinatal mortality and morbidity.  
Incidence of preterm birth is about 10-15% .  Prematurity contributes 
also to the reduced quality of life and neurosensory disability which 
increases with decreasing gestational age. Preterm birth may have huge 
psychosocial and emotional effects on the family, as well as being costly 
for health services. 
Preterm labour is defined by the world health organization  as the 
onset of labour, in a pregnancy before the completion of 37 weeks of 
gestation and after 20 weeks of gestation.   As per ACOG criteria (1997) 
Preterm labour is defined as the occurrence of regular uterine 
contractions (four or more in 20 minutes (or) eight (or) more in 1 hour) 
and with cervical changes (effacement equal to (or) more than 80% and 
dilatation equal to (or) greater than 1cm). Lower limit of surivial is 24 
weeks of gestation  in western countries and it is more than 32 weeks in 
India.  Upper limit of prematurity is 36 weeks.  
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In about 45-50% of cases of preterm labour the etiology remains 
obscure.  So attempts at prevention have not been very encouraging, 
but arrest of preterm labour continues to be the need of the hour.  
Obstetrician faces the challenge of survival of permature neonate as 
well as therapeutic alternatives available for management of preterm 
labour. 
The aim of care around preterm birth does not always involve 
prevention of preterm labour and birth.  In situation, where clinical 
considerations make it desirable to prolong pregnancy, the primary 
outcome considered is time gained to  
 Seek advise from perinatal care 
 Institute therapy  to improve lung maturity 
 If necessary move the mother to a centre with neonatal 
intensive care facilities. 
 
Currently main goal for use of tocolytic  therapy is to delay the 
birth so as to allow the use of corticosteroids for acclerating fetal lung 
maturity and maternal transfer to a tertiary care center and there by 
reducing neonatal morbidity and mortality.  By arresting preterm 
labour,  we can reduce the maternal guilt and anxiety about the cause 
for preterm birth of their baby and financial burden of preterm birth 
and care around preterm birth for families and communities.  
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   There are many number of tocolytic drugs, but unfortunately , 
none has been completely effective, because of questionable efficacy 
and potentially serious side effects out weigh the use of many tocolytic 
agents.  Beta adrenergic receptor agonists like Ritodrine , Terbutaline , 
Isoxsuprine  and others like magnesium sulphate , calcium channel 
blockers (nifedipine) Prostaglandin synthase inhibitors (Indomethacin), 
nitricoxide donors (glyceryl trinitrate) are tocolytic agents in use. In this 
study, comparison of  effectiveness of oral nifedipine with transdermal 
nitroglycerin in the inhibition of preterm delivery is being done.  
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AIM OF THE  STUDY 
 
 
 Comparison of oral nifedipine and transdermal nitroglycerin for 
tocolysis  in preterm labour in the following effects:  
1. Acute tocolytic  effect 
2. Duration of prolongation of pregnancy  
3. Neonatal outcome  
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REVIEW OF LITERATURE 
Preterm labour is a syndrome accounts for 45-50% of all preterm 
birth.  Despite advances in perinatal medicine in recent decades, the 
problem of preterm delivery continues to frustrate satisfactory 
reproductive outcome.  
Preterm labour is defined as the occurrence of regular uterine 
contractions (four or more in 20 minutes (or) eight (or) more in 1 hour) 
and cervical changes (effacement equal to (or) more than 80% and 
dilatation equal to (or) greater than 1cm) in women with intact fetal 
membranes and gestational age less than 37 weeks, as per ACOG 
criteria (1997). Currently however such clinical findings are now 
considered inaccurate predictors of preterm delivery   (ACOG 2003). 
Thus such explicit criteria do not appear in more recent guide lines 
(ACOG 2008) .   
The  pathogenesis of preterm labour may be  
 Progesterone withdrawl 
 Oxytocin initiation  
 Decidual activation 
Preterm labour may be characterised by the premature activation 
of final pathway of parturition.  It can be induced by infection, maternal  
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(or) fetal stress, choriodecidual bleeding, abnormal placentation – all 
will ultimately induce the release of inflammatory cytokines such as    
IL–6, IL-8, TNF alpha that will in turn , can cause myometrial activation, 
membrane activation , cervical ripening, that is the common pathway of 
parturition. 
 Premature ripening of the cervix is the predominant feature in 
women with incompetent cervix, premature activation of membranes is 
the key event, in women  with premature rupture of membranes and 
premature activation of myometrium is the cardinal feature in women 
with preterm labour and intact membranes .  During normal pregnancy, 
the uterus is under the effect of a series of inhibitors of uterine 
contractions, such as progesterone, relaxin, nitric oxide and 
prostacyclin.  The production of uterine contractions requires an 
increase in myometrial intra cellular calcium concentration. Calcium 
will bind to calmodulin and Calcium  - calmodulin complex bind with 
enzyme myosin light chain kinase and phosphorylate the short chain of 
myosin and by production of ATP causes muscle contraction. 
 Preterm labour can be classified into 
 Advanced Preterm labour – if cervix effaced more than  
                                                     80%  and  dilated more than 3cm . 
 Early preterm labour – when cervix effaced more than 80% and 
dilated more than  1cm but less than 3cm. 
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 Threatened preterm labour - cervix effaced less than 80% and 
dilated less than 1cm with cervical length less than 2.5cm. 
Prematurity  may be classified according to gestational age into 3 
groups. 
Severe prematurity – when birth occurs before 30 weeks. 
Intermediate prematurity – when birth occurs between 30 -34 weeks 
Late (or) mild  prematurity – between 34 and 37 weeks. 
 All the obstetrical resources should be used to avoid severe and 
intermediate prematurity and these births should occur in tertiary care 
centers with adequate neonatal intensive care facilities .  Mild 
prematurity can be managed in hospitals with level II nurseries. 
 From 26 – 34 weeks of gestation , the incidence of major neonatal 
morbidity ranged from 20 to 60% for Respiratory Distress syndrome,  
15-50% for patentductus arteriosus, 5 – 30% for sepsis and 2-25% for 
necrotising enterocolitis other insults are intraventricular Hemorrhage, 
periventricular leucomalacia and retinopathy of prematurity .  
Longterm morbidity  are cerebral palsy, blindness, refractory errors, 
hearing loss, intellectual impairments, behavioural problem, longterm 
respiratory ill health – broncho pulmonary dysplasia, other neurological 
disabilities.   
  There are number of drugs available for the acute treatment of 
preterm labour, to suppress the uterine activity, with different 
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pharmacological principles. A satisfactory pharmacological method  for 
the prevention of treatment of preterm labour is yet to be found.  Since 
tocolysis have both potential benefit and side effects to the neonate  and 
mother, their use should be based on well designed, controlled clinical 
studies. Tocolysis may be considered for women with suspected 
preterm labour who have had an otherwise uncomplicated pregnancy.  
A more recent meta analysis serves to confirm findings from earlier 
randomised clinical trials showing that maintenance therapy did not 
influence outcome in terms of incidence of preterm delivery. 
 The following conditions are needed for the use of tocolytic 
therapy. 
Criteria for Tocolysis are :  
1) Presence of regular uterine contractions with evidence of changes 
in cervix. 
2) A gestational age (24-36 weeks) at which treatment will benefit 
the fetus. 
3) The maternal and fetal benefits must outweigh the risks and side 
effects of tocolytic use. 
4) Absence of medical/ obstetrical contra indications to inhibition of 
labour (or) use of tocolytics. 
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Continuation of Pregnancy is contraindicated in the following 
conditions  
Contraindications to tocolysis are :  
1) Intra uterine fetal death 
2) Fetal distress /congenital anomaly  
3) Chorioamnionitis 
4) Severe intra uterine growth restriction 
5) Severe (or) undiagnosed maternal vaginal bleeding 
6) Eclampsia (or) severe pre eclampsia 
7) Premature rupture of membranes. 
If any of the above conditions are present, pregnancy is terminated as 
early as possible. 
 
Pharmacological agents available at present  
 Tocolytic agents currently utilised for treating preterm labour 
include, 
1. Beta adrenergic receptor agonist (Isoxsuprine /Ritodrine/ 
Terbutaline)  
2. Magnesium sulphate 
3. Calcium channel blockers (nifedipine) 
4. Oxytocin receptor antagonists 
5. Prostaglandin synthase inhibitors (Indomethacin) 
6. Nitric oxide donors (glyceryl trinitrate) 
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1. Beta adrenergic receptor agonists :  
a) Isox suprine :  
 Isox suprine was first introduced in the management of preterm 
labour in 1961 (Bishop and wouteriz).  It was the first Beta mimetic 
agent to be studied ; Due to its cardiac side effects and failed to show 
any benefit in either prolonging the pregnancy (or) reducing the 
perinatal mortality, this drug is not much used in arrest of preterm 
labour. 
b) Ritodrine :  
 Any Beta2 sympathomimetic drug is relatively, but not 
completely specific for Beta 2 rather than the Beta 1 receptor.  Ritodrine 
is used as IV infusion with 5% dextrose, because of risk of sodium 
which can cause water retention, it is not used with normal saline.  
Nausea , vomiting, tremor , palpitation, nervousness, restlessness,  are 
frequently reported, as side effects of ritodrine.  Pulmary edema is more 
fatal complication of this drug. 
c) Terbutaline :  
 Terbutaline was commonly used previously , like ritodrine it can 
cause pulmonary edema.  When longterm terbutaline given by 
subcutaneous pump,  can cause sudden maternal death and myocardial 
necrosis in neonate, when it is used for 12 weeks.  Oral terbutaline 
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therapy to prevent preterm delivery has also not been effective .  
Terbutaline did not significantly prolong pregnancy , prevent preterm 
delivery (or) improve neonatal outcome. 
2) Magnesium Sulphate :  
 Magnesium sulphate is most commonly used for the prevention 
of treatment of seizures associated with preeclampsia but its tocolytic 
effect has been recognised since 1959.  The therapeutic level ranged for 
both these indications is plasma concentration of 4-8 mmol-L.  Higher 
concentration than this, produce neuromuscular blockage, respiratory 
depression and cardiac arrest. Further more, it crosses the placenta, and 
the new born may be drowsy and exhibit decreased muscle tone at 
delivery resulting in hypoventilation requiring assisted ventilation.  
Longterm administration can case fetal/neonatal hypocalcemia. 
3) Calcium Channel Blockers : (nifedipine)  
 Myometrial activity is directly related to cytoplasmic free calcium 
and reduction in its concentrations inhibits  contractions.  Calcium 
channel blockers, act to inhibit by a variety of mechanisms, the entry of 
calcium through channels in the cell membranes.  Although they were 
developed to treat hypertension, their use to arrest preterm labour has 
been the subject to research since the late 1970s. There are fewer 
maternal side effects like flushing, headache, dizziness, palpitation and 
no apparent fetal effects.  In (1997) papatsonis etal and In (2002) king et 
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al, in recent meta analysis of comparing nifedipine with Ritodrine for 
the treatment of preterm labour – suggested that nifedipine is more 
effective in delaying delivery and is associated with reduced NICU 
admission .  Studies on nifedipine was conducted by Ganla (1999) India  
it was used for 26-36 weeks of gestational age.  In carr (1999) United 
States – recruited the patient in 24-33 weeks of gestational age.  Sayin 
(2004) Turkey study conducted in women with singleton (or) twin 
pregnancy and intact membranes who had been in active preterm 
labour. Amorim (2009) Brazil taken the women with 24 -34 weeks of 
gestational age for study. In this study comparative study of oral 
nifedipine with transdermal nitroglycerin patch was done.  A 
systematic review using adjusted indirect comparison between 
nifedpine and atosiban concluded that nifedipine was associated with a 
non significant trend towards increased delay in delivery by 48 hours , 
in cochrane review. 
4) Oxytocin receptor antagonist : (Atosiban) 
 In humans , the myometrium becomes increasingly sensitive to 
oxytocin , because of increased oxytocin receptor activity mainly in late 
pregnancy, and it is also shown following the onset of preterm labour. 
(Takahashi etal – 1980)  
 Atosiban is nonapeptide oxytocin analog, competitive  antagonist 
of oxytocin induced contractions. A data from (Romero etal 2000) 
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implies that atosiban can delay delivery when compared to placebo.  In 
2004, Goodwin reviewed  the efficacy of atosiban, and it is widely used 
for tocolysis. 
5. Prostaglandin synthase inhibitors (Indomethacin) 
 Drugs that inhibit prostaglandins have been of considerable 
interest because prostaglandins are intimately involved in contractions 
of normal labour. These drugs previously suggested for as an 
alternative to beta adrenergic agonists for inhibition of preterm labour, 
particularly in patient with cardiac disese (or) hyper thyroidism.  They 
are not used because of fear of premature closure of ductus arteriosus 
pulmonary Hypertension and necrotising enterocolitis in the fetus. 
6. Nitric Oxide donors :  
 Nitric oxide is endogenously occuring bio molecule and can be 
given in the form of nitric oxide donor.  The first recorded use of an 
nitric oxide donor in pregnancy was reported in British Journal 1882, 
when Amyl nitrate was used to deliver, morbidly adherent placenta. 
 Glyceryl trinitrate was used IV, as a uterine relaxant , to aid 
breech extraction (Greenspom), and to assist in replacing an inverted 
uterus and incases of removal of adherent placenta.  Nitric oxide by 
increasing Cyclic GMP and cause myometrial relaxation .  It can cause 
cardiovascular side effects like  tachy cardia and hypotension.  There 
are reports of use of nitric oxide donors suggest that they are effective 
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tocolytics in comparison  with placebo delaying delivery for 48 hrs  
(smith etal, 1999)  . Study by Afifa etal (2006),  showed that glyceryl 
trinitrate can be used as safer tocolytic agent.   
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MATERIALS AND METHODS 
 
Study on tocolysis in preterm labour was conducted in 
Government Rajaji Hospital from December 2010 to November 2011. 
100 women with preterm labour randomly selected from the pregnant 
women attending  antenatal OP and from labour ward from the 
department of obstetrics and gynecology, Government Rajaji Hospital , 
Madurai .  Out of which 50 women were recruited for oral nifedipine 
and another 50 women were recruited for transdermal  nitroglycerin 
patch. 
 The patients recruited for this study fulfilled the following 
inclusion criteria. 
Inclusion criteria :  
1) Singleton pregnancy with Gestational age from 28 weeks to 36 
weeks 
2) Regular painful uterine contractions minimum of two , every ten 
minutes and for more than 1 hour. 
3) With intact membranes 
4) cervical dilatation less than 1cm to 3 cm 
5) No medical condition obviating medical therapy 
If the following conditions are present, those patients were excluded 
from the study. 
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Exclusion criteria:  
1) Premature rupture of membranes 
2) Fetal distress 
3) Major fetal congenital anomalies 
4) Chorioamnionitis 
5) Antepartum hemorrhage 
6) Sensitivity or  contra indication to nifedipine/nitrates. 
             All women meeting the eligibility criteria, were properly 
informed about the aims of the study and those who agreed to 
participates signed a consent form.  Those women who were dignosed 
to have preterm labour were admitted in labour ward in the 
observational areas, where continuous monitoring was possible.  A 
detailed history was obtained, under aseptic precautions, general , 
systemic , speclum and pervaginal examinations were done .  Base line 
pulse,  blood pressure and fetal heart  rate were recorded .  The findings 
were recorded on a predesigned proforma.  Investigations like Blood 
hemoglobin, blood grouping and Rh typing, urine – albumin, sugar, 
blood sugar , urea, serum creatinine and ultrasonography were done.  
Two doses of betamethasone (12mg IM 24 hours apart) were 
administrated to all cases .  Prophylatic antibiotics were also given for 
further prevention of infection. 
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 50 patients were randomly selected for oral nifedipine and were 
designated as group I and the other 50 patients were selected for 
transdermal nitroglycerin patch and were designated as group II and 
time needed for tocolysis and prolongation of pregnancy and the 
neonatal outcomes were observed.  The results are tabulated in 
performed proforma and meticulously  analysed. 
ORAL NIFEDIPINE (Group – I)  
 For women randomised to oral nifedipine, initially administered 
20mg of nifedipine in the form of 10mg tablets  x 2 tablets , and 10mg 
repeated after 30minutes if there is contractions.  Then 10mg oral 
infedipine repeated every six hours, till the contractions stop. 
Monitoring :  
 Maternal pulse  rate , blood pressure , fetal heart rate  and uterine 
contractions were monitored initially every 15 minutes for first two 
hours.  Then every two hours for 6 hours and every 6 hours for 48 
hours.  
Treatment was discontinued, if therewas :  
1) Fall of Bp less than 90/60mmhg (or)  
2) If the pulse rate is more than 100/mt (or) 
3) If the patient had premature rupture of membranes (or)  
4) If there was persistent uterine contractions even after 48 hours.   
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TRANSDERMAL  NITROGLYCERIN PATCH 
APPLIED OVER THE ABDOMEN 
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5) If signs of fetal distress. 
Side effects like dizziness, nausea noted in few patients. 
 The treatment was considered successful if uterine contractions 
subsided and tocolysis was achieved for more than 48 hours.   This 
minimum time interval was chosen, because it was considered 
sufficient for the action of the administered steroids to decrease 
respiratory complications  in premature neonate and for transfer to well 
equipped centre for further management of preterm neonate. 
 After contractions stopped, till 37 weeks of gestation patient was 
reviewed weekly once (or) follow up done, till delivery – if delivered 
before 37 weeks. 
TRANSDERMAL NITROGLYCERIN PATCH (GROUP –II) 
 Women in preterm labour recruited for transdermal nitoglycerin 
study , transdermal nitroglycerin patch (25mg ) (TTS -5) was directly 
applied to the skin of abdomen. 
MONITORING :  
 Throughout, maternal pulse , blood pressure fetal heart rate were 
monitored every 15mts and occurence of uterine contractions also 
monitored every 15mts in the first two hours. Then, two hourly for 6 hrs 
followed by 6th hourly  for 48 hours.   
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Treatment  was discontinued if 
1. patient complaining  of any headache ,  
2. Hypotension less than 90/60mmhg ,   
3. Pulserate more than 100/mt ,  
4. If the patient had premature rupture of membranes  
5. If there was persistent uterine contractions even after 48 hours.  
6. If signs of fetal distress. 
 After contractions stopped, patient was reviewed every week 
upto 37 weeks  of gestation .  Otherwise till delivery if it occurs less than 
37 weeks. 
 The results of the study is tabulated and analysed meticulously 
STATISTICAL TOOLS  
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta. 
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and  'p'  values were calculated. Kruskul 
Wallis chi-square  test was used to test the significance of difference 
between quantitative variables and Yate’s chi square test for qualitative 
variables. A 'p' value less than 0.05 is taken to denote significant 
relationship. 
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DRUG PHARMACOLOGY 
NIFEDIPINE :  
 Influx of calcium ions play an important role in uterine 
contractions . The production of uterine contraction requires an increase 
in myometrial intracellular calcium concentration. Calcium will bind to 
calmodulin and Calcium  - calmodulin complex bind with enzyme 
myosin light chain kinase and phosphorylate the short chain of myosin 
and by production of ATP causes muscle contraction. The activity of 
myosin light chain kinase is central to the process of muscle contraction.  
 Nifedipine has prominent smooth muscle relaxant property. It is the 
prototype Dihydropyridine (lipophilic) group of calcium channel 
blockers.  Dihydropyridine are most potent calcium channel blockers.  It 
acts on voltage sensitive L – type (Long lasting current ) channels in 
uterine  musculature  and there by decrease the intracellular availability  
of calcium ion and cause uterine relaxation. 
 Nifedipine has rapid onset and short duration of action .  
DOSAGE :  
 Available as 5mg , 10mg, also as 10mg, 20mg, sustained released 
tablets. 
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PHARMACOKINETICS :  
BIOAVAILABILITY :   
 It is about 30 – 60% , because of high first pass metabolism and 
with marked inter and intra individual variation .  Peak occurs at 1 – 3 
hours. 
DISTRIBUTION :  
 It bound to plasma proteins and have extensive tissue 
distribution. 
METABOLISM :  
 Nifedipine is metabolised in liver and excreted in urine.  
ELIMINATION:  
Elimination t½ of nifedipine is ranging from 2-6 hours.  
GLYCERYL TRINITRATE : 
 Nitric Oxide is basically responsible for relaxation of smooth 
muscles of myometrium.  This is brought about by formation of Nitric 
oxide – CGMP from L-arginine.  In the early pregnancy, due to  
decreased excretion of nitrite and CGMP, plasma levels increases 
thereby indicating enhanced formation of nitric oxide .  The myometrial 
concentration of Nitric oxide increases significantly, but in late 
pregnancy there is reduction of nitric oxide in myometrium and 
decidua.  There fore contractile status increases towards term.  Conrad 
et al localised nitric oxide in syncytio trophoblast of human placenta. 
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COMPOSITION :  
 Transdermal therapeutic system (TTS) containing 25mg (TTS – 5) 
50mg (TTS-10) and  75mg (TTS-15) nitro glycerin are available for use. 
PROPERTIES :  
 TTS is a flat multilayer system designed to delvier nitro glycerine 
continuously through a release membrane.  TTS -5 denotes the nominal 
amount of nitro glycerine in mg delivered by the system per 24 hours.  
The nitro glycerine content will be 25mg  and the rate of drug release 
per hour is  0.4mg. 
ABSORPTION :  
 Following single application of nitroderm TTS, placental 
concentration of nitro glycerine reach a plateau within 2 hours.  The 
plateau is maintained over the recommended period of application. 
DISTRIBUTION :  
 The same plasma levels are obtained regardless of the site of 
application of the patch and the distribution of the drug is equal.  
METABOLISM :  
 Transdermal glyceryl trinitrate is rapidly metabolised by 
glutathione dependent organic nitrate reductase in liver and excreted in 
urine.  
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ELIMINATION :  
 Plasma concentration drop below the level of detection within 1 
hour after removal. 
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Age distribution 
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RESULTS AND ANALYSIS  
 The study was designed with a total sample of randomly selected 
100 women who were in preterm labour out of which 50 women in 
randomly allotted for oral nifedipine in group I and another 50 women 
were randomly selected for Transdermal nitroglycerin patch in group 
II. All preterm labour women on study were given corticosteroids and 
prophylactic antibiotics. After inspection of the collected data from our 
study, the following results were observed .  
 Base line characteristics of the two groups were comparable.  
Group I : Pregnant women with preterm labour given oral nifedipine      
            ( 50 cases) 
Group II : Pregnant women with preterm labour given transdermal  
       nitroglycerin  (50 cases). 
A : PROFILE OF CASES STUDIED  
Table 1  
Age distribution 
Age group Group I  Group II 
No % No % 
< 20 years 12 24 8 16 
20 – 24 years 17 34 19 38 
25 – 29 years 14 28 16 32 
30 years and above 7 14 7 14 
Total 50 100 50 100 
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Range 18- 35 years  18-32 years 
Mean 23.9 years 24.0 years 
SD 4.7 years 4.1 years 
‘p’ 0.7165  
Not significant 
 
The age distribution of the two groups has no significant 
difference. (‘p’ = 0.7165 Not Significant).  The Maximum number of 
patients in both groups fall in age group between 20-24 years, 34% (17 
out of 50) in group I and 38% (19 out of 50)  in group II. 24% (12 out of 
50) were teenagers in group I, when compared to group II it was 16% (8 
out of 50). In both the groups 14% (7 out of 50) were more than 30 years 
of age. The mean age group in the study subject was 23.9 years in group 
I and 24 years in group II. 
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Table 2 
Antenatal care 
Age group Group I  Group II 
No % No % 
Booked 23 46 19 38 
Unbooked 27 54 31 62 
Total 50 100 50 100 
‘p’ 0.5433  
Not significant 
 
 
 There is no significant difference in the Antenatal care received 
by the 2 groups of patients. ( P Value = 0.5433 Not significant) 46% (23 
out of 50) belonged to booked and 54% (27 out of 50) belonged to 
Unbooked in group I, Whereas 38% (19 out of 50) belonged to booked 
and 62% (31 out of 50) belonged to Unbooked in group II.  
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Table 3 
Parity 
Gravida Group I  Group II 
No % No % 
Primigravida 26 52 24 48 
2 11 22 13 26 
3 and above 13 26 13 26 
‘p’ 0.8961  
Not significant 
 
 There is no significant difference in the parity in both group I and 
group II (P value = 0.8961 Not significant). Primigravida comprised  of 
about 52% (26 out of 50) in group I and 48% (24 out of 50) in group II 
Multiparous women in pre-term labour comprised of about 48% (24 out 
of 50) in group I and 52% (26 out of 50) in group II. Parity distribution 
was almost equal in both groups. 
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Table 4 
History of preterm  labour / abortion 
History of  Group I Group II 
No % No % 
Preterm labour 
Yes 
No 
 
11 
39 
 
22 
78 
 
9 
41 
 
18 
82 
‘p’ 0.8026  
Not significant 
Abortion 
Yes 
No 
 
9 
41 
 
18 
82 
 
10 
40 
 
20 
80 
‘p’ 0.8126  
Not significant 
 
Pre-term labour in previous pregnancy was 22% (11out of 50) in 
group I and 18% (9 out of 50) in group II. There is no significant 
difference in the history of pre-term labour between the 2 groups of 
patients. (p=value 0.8126). History of previous abortion present in 18% 
(9 out of 50) in group I and 20% (10 out of 50) in group II patients. There 
is no significant difference in both the  group of patients.  
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Table 5 : Gestational age on admission and mean 
prolongation 
 
Gestational Age 
( in weeks) 
No.of cases Prolongation  
(Mean) (In days) 
Group I Group II Group I 
 
GroupII 
No % No % 
28 – 30  9 18 6 12 32.8  21.8 
31-32 19 38 16 32 24.8 14.8 
33-34 17 34 21 42 14.0 13.8 
35-36 5 10 7 14 4.8 7.7 
Total 50 100 50 100 20.74 14.1 
  
Though there was not much significant difference in the 
gestational age on admission in both groups, the time of prolongation of 
pregnancy varied considerably in both groups. 
 38%  ( 19 out of 50) of group I study subjects were in 31-32 weeks 
of gestation and 32% (16 out of 50) in group II study subjects were in 31-
32 weeks of gestation. 10% in group I were in more than 34 weeks, and 
14% in group II were in more than 34 weeks. Mean prolongation in 
group I was 20.74 days. In group II, it was 14.1 days. 
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 Mean duration of prolongation of pregnancy varied with 
gestational age on admission considerably both in group I and group II. 
When the gestational age was less than 30 weeks, the mean 
prolongation was 32.8 days in group I and it was 21.8 days in group II. 
When gestational age was between 31 – 32 weeks, the mean 
prolongation was 24.8 in group I where as in group II it was 14.8 days. 
When gestational age was between 33 and 34 weeks, mean  
prolongation in group I was 14 days and in group II it was 13.8 days. 
When the gestational age between 35 – 36 weeks prolongation 4.8 days 
in group I and 7.7 days in group II. 
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Table 6 
Presentation 
Presentation Group I Group II 
No % No % 
Head 46 92 45 90 
Breech 4 8 5 10 
‘p’ 0.5  
Not significant 
 
 The distribution of the presenting part in both groups were equal. 
Majority of the patients in both groups had cephalic presentation 92%  
(46 out of 50) in group I and 90% (45 out of 50) in group II.  
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Table 7 : Cervical effacement 
Cervical 
effacement 
No.of cases Prolongation  
(Mean) (In 
days) 
‘p’ 
Group I Group II Group 
I 
 
Group 
II No % No % 
25% 18 36 21 42 33.5 22.1 0.003 
Significant 
50% 19 38 14 28 20.6 13.1 0.0518  
Not Significant 
75% 13 26 15 30 3.3 2.8 0.3388 
Not significant 
 
 Cervical effacement in both the groups had no  significant 
difference . 36% (18 out of 50) in group I had 25% effacement and 42% 
(21 out of 50) in group II had 25% effacement. 38% (19 out of 50) in 
group I and 28% (14 out of 50) in group II had 50% effacement. 26% (13 
out of 50) in group I and 30% (15 out of 50) had 75% effacement. 
 Cervical effacement considerably influenced on the mean 
prolongation of pregnancy, after tocolysis in both groups. Group I has 
mean prolongation of pregnancy significantly when compared to group 
II when the cervical effacement was 25%. ( p = 0.003 signficant). 
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Table 8 : Cervical dilation 
Cervical 
dilation 
( in cms) 
No.of cases Prolongation  
(Mean) (In 
days) 
‘p’ 
Group I Group II Group 
I 
 
Group 
II No % No % 
< 1 14 28 18 36 33.2 21.7 0.0044 
Significant 
1 17 34 16 32 25.4 15.1 0.0128 
Significant 
2 10 20 8 16 11.0 4.0 0.2431 
Not significant 
3 9 18 8 16 3.2 2.8 0.645 
Significant 
 
 In mean prolongation of pregnancy, group I was having 33.2 days 
whereas in group II, it was 21.7 days (p = 0.0044 significant), when the 
cervical dilatation less than 1 cm. Mean prolongation with group I was 
25.4 days and 15.1 days in group II ( p = 0.0128 significant), when the 
cervical dilatation was 1 cm. With 2 cm dilatation of cervix, mean  
prolongation was 11 days in group I and 4 days in group II. When the 
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cervical dilation was 3 cms, mean prolongation with group I was 3.2 
days and with group II was 2.8 days ( p = 0.0458 significant). 
 Mean prolongation with group I was significant when compared 
to group II, in case of cervical dilatation 1cm or less than 1 cm. 
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 Table 9 : Station of presenting part 
Station of 
presenting part 
No. of cases Prolongation  
(Mean) (In days) 
‘p’ 
Group I Group II Group   
I 
 
Group 
II No % No % 
-3  20 40 12 24 29.2 15.25 0.0011 
Significant 
-2 21 42 29 58 20.43 15.54 0.4982  
Not 
significant 
-1 9 18 9 18 2.67 1.13 0.4138 Not 
significant 
 
There is no significant difference in the distribution of station of 
presenting part in both the groups. In both groups 18% (9 out of 50) had 
presenting part at -1 station, and 82% (41 out of 50) in both the groups 
had the presenting part at and above -2 station. Mean prolongation of 
pregnancy was 29.2 days in group I and 15.25 days in group II ( p = 
0.0011 significant). When the station was -2, mean prolongation with 
group I was 20.4 days with group II was 15.5 days. Mean prolongation 
was 2.6 days in group I and 1.1 day in group II when the presenting 
part was at -1 station.  
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B : EFFICACY OF THE TWO DRUGS 
Table 10 : Bishop score 
Bishop score No.of cases Prolongation  
(Mean) (In 
days) 
‘p’ 
Group I Group II Group 
I 
 
Group 
II No % No % 
Upto 4  37 74 36 72 26.9 17.9 0.0023 
Significant 
Above 4  13 26 14 28 3.3 2.5 0.1572  
Not significant 
 
 About  74% (37 out of 50) in group I and about 72% (36 out of 50) 
had bishop score upto 4, here the mean prolongation with group I was 
26.9 days and 17.9 days with group II ( p = 0.0023 significant. When the 
bishop score was above 4, mean prolongation with group I was 3.3 days 
and with group II was 2.5 days ( p = 0.1572 not significant).  
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Table 11 
Time needed for Tocolysis 
Variable Time needed for tocolysis 
Group I Group II 
Range 2-12 hours 2-12 hours  
Mean 4.55 6.09 
SD 3.05 3.2 
‘p’ 0.006  
Significant 
 
Time needed for Tocolysis ranging between 2-12 hours in both 
the groups. Mean time needed for Tocolysis in group I was 4.55 hours 
and in group II it was 6.09 hours. ‘P’ Value = 0.006, significant 
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Table 12 
Complications 
Complications Group I Group II 
No % No % 
Dizziness 1 2 2 4 
Nausea 2 4 - - 
Tachycardia - - 2 4 
Headache - - 7 14 
‘p’ 0.0437 
Significant 
 
There is significant difference in the incidence of complications 
among the 2 groups of patients p(0.0437). Among group I, it was about  
6% (3 out of 50) and in group II 22% (11 out of 50). Side effect with 
nifedipine was dizziness, Nausea. Headache was the main side effect 
seen with nitroglycerin No major systemic complications were faced in 
group I. 
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Table 13 : Gestational age at delivery 
Gestational age at delivery 
( in weeks) 
Group I Group II 
No % No % 
28-30 1 2 2 4 
30-32 1 2 2 4 
32-34 6 12 8 16 
34-37 29 58 30 60 
>37 13 26 8 16 
Mean 35.49 weeks 34.89 weeks 
P 0.1563 Not significant 
 
When the gestational age at delivery was compared in both 
groups, it differed significantly. 4% (2 out of 50) were delivered in less 
than 32 weeks in group I, whereas 8% (4 out of 50) were delivered in 
less than 32 weeks in group II. In group I 26% (13 out of 50)  were 
delivered after 37 weeks, it was 16% (8 out of 50) in group II. Mean 
gestational age at delivery in group I was 35.49 weeks, whereas in 
group II it was 34.89 weeks. 
 
 
 
  
55 
 
DURATION OF PROLONGATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20.74
13.5
0 3 6 9 12 15 18 21
Mean duration of prolongation (in days)
Group I
Group II
56 
 
Table 14 : Duration of prolongation 
Duration of prolongation Group I Group II 
No % No % 
Same day - - 2 4 
1 day 1 2 3 6 
2 days 4 8 9 18 
3 – 7 days 11 22 7 14 
1 week – 2 weeks 3 6 9 18 
2 – 4 weeks 15 30 16 32 
> 4 weeks 16 32 4 8 
Range 1-60 0-44 
Mean 20.74 13.5 
P 0.0193 Significant 
 
 The treatment delivery interval differed significantly in both 
groups. About 4% ( 2 out of 50) delivered on the same day in group II. 
Where as no one had delivered on the same day in group I. 6% 
delivered in 1 -2 weeks in group I and 18% in group II. 22% (11 out of 
50) in group I and 14%(7 out of 50) in group II delivered within 3 – 7 
days. When delivery after 4 weeks was compared 32% ( 16 out of 50) in 
group I and 8% (4 out of 50) in group II, delivered after 4 weeks ( p = 
0.0059 significant). 
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 Table 15 : Acute tocolytic effect  
Treatment delivery interval Group I Group II 
No % No % 
Upto 2 days 5 10 14 28 
> 2 days 45 90 36 72 
Total 50 100 50 100 
‘p’ 0.0414 Significant 
 
The acute tocolytic effect between the 2 groups was significantly 
different ( p = 0.0414 significant). Only 10% (5 out of 50) in group I 
delivered within 2 days but in group II it was 28% ( 14 out of 50). 90% 
(45 out of 50) were crossed the period of 48 hours for effective action of 
steroids in group I. But in group II only 72% (36 out of 50) crossed the 
period of 48 hours.  
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Table 16 
Birth weight 
Birth weight Group I Group II 
No % No % 
< 2.5 kgs 29 58 34 68 
> 2.5 kgs 21 42 16 32 
Mean 2.32 kgs  2.19 kgs 
‘p’ 0.1778  
Not significant 
 
 There is no much significant difference in the birth weight of the 
babies in both the groups. In group I mean birth weight was 2.32kg 
where as in group II mean birth weight was 2.19kg. 
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Table 17 
Apgar Score 
Apgar score at Group I Group B ‘p’ 
Mean SD Mean SD 
1 minute 5.02 0.96 4.46 1.09 0.0072 
Significant 
5 minutes 6.38 1.14 5.8 0.95 0.0075  
Significant 
 
 Babies born in group I had mean apgar 5.02 and in group II mean 
apgar 4.46. in 1 minute ‘p’ value = 0.0072 (significant). 5 minute apgar 
was 6.38 in group I babies  and it was 5.8 in group II babies ‘p’ value = 
0.0075 (significant).  
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Table 18 
Neonatal morbidity 
Neonatal Morbidity
(NICU admission) 
Group I Group II 
No % No % 
Yes 7 14 16 32 
No 43 86 34 68 
‘p’ 0.05  
Significant 
 
Admission in neonatal ward differed significantly. Only 7 Babies 
(14%) in group I got admitted in neonatal ward where as in group II 16 
babies (32%) got admitted. This indicates, nifedipine successfully 
reducing the neonatal admission and had the better perinatal out come.   
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DISCUSSION  
 
 
 On analysing the outcome data, tocolysis with oral 
nifedipine is considered safe with good therapeutic efficacy 
compared to transdermal nitroglycerin patch.  
 When this data was compared with previous study, baseline 
characteristics did not differ significantly. In the study by Amorim 
et al (2009-11), Pregnant women aged between 18 and 40 yrs with 
singleton pregnancies. In our study, the patients in Group-I 
between 18 to 35 yrs and in Group-II between 18 to 32 years were 
recruited. Gestational age at inclusion was between 24 to 34 weeks, 
in Amorim study . Gestational age at entry differed considerably 
in each study group. In the study by Taherian (2007), it was 26-36 
weeks. In Kashanian (2005) study, gestational age varied from 26-
34 weeks. Gastational age between 26-36 weeks recruited in Ganla 
(1999) study. Papatsonis (1997) study included the 20-33 weeks 
gestational age. In the study by Smith GN (2007), gestational age 
between 24 to 32 weeks included. In afifa etal (2007) 28 weeks to 36 
weeks were taken for study. In our study, the patients recruited 
had the gestational age from 28 to 36 weeks. Maximum number of 
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patients  fell in the gestational age group of 31 to 34 weeks (74%) 
both in nifedipine and in nitroglycerin group.  
 Cervical dilatation in our study in the range of 3cm or less, 
where as in the study by Amorim (2009-11), cervical dilatation was  
2-4cm and bag full of water. In Afifa (2007) study, cervical 
dilatation 0-4cm. In study by KOKs (1998), cervical dilatation was 
2cm (or) less. Cervical dilatation influenced much on the 
prolongation of pregnancy when cervical dilatation exceeded more 
than 2cm, tocolytic efficacy was minimal. Mean prolongation of 
pregnancy with nifidipine in study by Agustin et al (2011) was 5.8 
days. In Afifa study with nitroglycerin patch, mean prolongation 
was 2 days. In our study, when cervical dilatation was 3cm, mean 
prolongation of pregnancy with nifedipine was 3.2 days and with 
nitroglycerin was 2.8 days.  
 In study by Amorim (2009) nifedipine 10mg sublingually 
given, repeated after 30 minutes. Then 20mg orally every 6 hours 
for atleast 24 hours. In our study 20mg nifedipine given orally, 
followed by 10mg after 30 minutes and 10mg every 6 hours till the 
contractions stopped. In Amorim study (2009), Nitroglycerin 
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patch, used was 10mg, in our study nitroglycerin transdermal 
patch 25mg was used.  
 In study by Amorim (2009), no significant difference of 
frequency of side effects presented by patients, except for 
headache which was about 30%, who received nitroglycerin and 
8.3% with nifedipine. In our study headache occurred in 11 
patients (22%) who received nitroglycerin and dizziness (2%), 
Nausea (4%) in patients had oral nifedipine. Because of minimal 
side effects nifedipine is considered safer. Study by Agustin et al 
(2011) showed that nifedipine appeared to be effective tocolytic 
agent and  had improvement in neonatal outcome.  
 The success rate of acute tocolysis was 87.5% with nifedipine 
and 84.6% with nitroglycerin in Amorim (2009) Study. In the study 
conducted here success rate of acute tocolysis with oral nifedipine 
was 90% and with nitroglycerin was 72%.  
 The time average needed for tocolysis was 5.8 hours with 
oral nifedipine and 6.6 hours with nitroglycerin. In our study time 
needed for tocolysis was 4.55 hours for oral nifedipine and 6.09 
hours for transdermal nitroglycerin patch.  
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 Mean prolongation of pregnancy upto more than 4 weeks 
with nifedipine was 32% and with nitroglycerin was 8% in our 
study.  
 Tocolytic efficacy of oral nifedipine was comparatively better 
than nitroglycerin, because of better acute tocolytic effect, reduced 
maternal complication, good neonatal outcome and lower preterm 
delivery rate and with good prolongation of pregnancy.  
 Safety, efficacy, acceptability limits the usage of a drug. 
Nifedipine is considered to be safer for its ease of use, metabolism 
and elimination of drug with minimal side effects. While efficacy 
was studied, nifedipine acts as a good tocolytic, for effective action 
of corticosteroids and to provide time for the patient to get 
transferred to tertiary neonatal care unit.  
 As a secondary analysis, an economic evaluation of the trial 
was done. Cost of oral nifedipine is less when compared to 
transdermal glyceryl trinitrate, which is costlier. Because all of 
these, good acute tocolytic efficacy, less maternal side effect good 
neonatal outcome, less cost, nifedipine was superior to glyceryl 
trinitrate. The rapid and effective action obtained with nifedipine, 
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its simplicity of administration and safety, suggest that nipedifine, 
makes major contribution to the management of preterm labour.  
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SUMMARY  
 
 
 This study was conducted in 100 patients with preterm 
labour who were randomly selected from the Department of 
Obstetrics and gynecology, those who attending the antenatal OP. 
They were divided into Group I (50) and Group II (50) randomly. 
Group I received oral nifedipine and Group II received 
transdermal nitroglycerin patch. The results were analysed and 
studied.  
1. Age:  
 Age distribution between the two groups was found to be 
equal. Majority of the patients were belonged to age group of 20-29 
years (31 patients in group I (62%) and 35 patients in group II 
(70%). In both the groups 14% (7 patients) were belonged to 30 
years and above.  
2. Antenatal Care:  
 Most of the patients in this study group were found to be 
unbooked (54% in group I and 62% in group II). 46% in group I  
and  38% in group II were found to be booked.  
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3. Parity: 
 Parity distribution was found to be equal in group I and 
group II. Half of them were found to be primigravida (52% in 
group I and 48% in group II.  
4. History of Preterm labour / Abortion  
 Previous History of preterm labour was present only in 
minority of patients. (22% in Group I and 18% in group II). History 
of abortion also present in minority of patients. (In group I 18% 
and in group II 20%)  
5. Gestational age on admission:  
 Majority of the patients in the study groups were found to be 
in the gestational age between 31 – 34 weeks.  
6. Presentation:  
 92% in group I had cephalic presentation and 90% in group 
II had cephalic presentation. 8% in group I and 10% in group II 
had podalic presentation.  
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 From the above analysis, this study group has equal 
distribution of cases both in group I and group II as far as age, 
parity, booking, presentation, gestational age on admission, 
previous history of abortion and preterm labour were concerned.  
7. Cervical effacement at the time of treatment:  
 Both in group I and group II, about 1/4th of the patients (26% 
in group I and 30% in group II) had belonged to 75% effacement. 
36% in group I and 42% in group II had 25% effacement and 38% 
in group I, 28% in group II had 50% effacement. The more the 
effacement lesser is the duration of prolongation of pregnancy 
both in group I and group II. Mean prolongation of pregnancy was 
33.5 days in group I and 22.1 days in group II, when the 
effacement of 25%.  3.3 days prolonged in group I and 2.8 days 
prolonged in group II, when the effacement was 75%.  
8. Cervical dilatation at the time of treatment:  
 18% in group I and 16% in group II had 3cm dilatation. 62% 
in group I and 68% in group II had cervical dilatation of 1cm and 
less than 1cm. When the cervical dilatation 3cm prolongation of 
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pregnancy less in both the groups. Mean prolongation of about 3.2 
days with group I and about 2.8 days with Group II.  
9. Station of presenting part:  
 There is no significant difference in the distribution of station 
of presenting part in both the groups. 82% patients in both groups 
had presenting part at and above- 2 stations. 18% of patients had 
presenting part at -1 station both in group I and Group II.  
 Duration of prolongation of pregnancy decreases, when the 
station of the presenting part comes down, in both groups. Mean 
prolongation with group I  was 29.2 days and with Group II was 
15.25 days when the station was above -2.  
10. Bishop Score  
 About 74% in group I and 72% in group II had bishop score 4 
or less than 4. Here the mean prolongation of pregnancy in group I 
was 26.9 days whereas in group II it was 17.9 days. When the 
bishop score more than 4,  mean duration of prolongation was less.  
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11. Time needed for tocolysis:  
 Both in group I and group II – time needed for tocolysis 
ranged from 2 - 12 hours. Mean time needed for tocolysis in group 
I was 4.55 hours when compared with group II, it was 6.09 hours.  
12. Complications:  
 Only 6% of patients in group I and 22% in group II had side 
effects. Dizziness (2%), nausea (4%) were found in group I where 
as headache (14%) was main side effect with group II. It shows, 
group I has minimal side effects and it is safer.  
13. Gestational age at delivery:   
 About 26% in group I delivered after 37 weeks whereas in 16% in 
group II delivered after 37 weeks.  
14. Duration of Prolongation:  
 In group I, 32% were delivered after 4 weeks, but in group II 
only 8% were delivered after 4 weeks. 4% in group II were 
delivered on the same day, but none in group I.  
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15. Acute tocolysis:  
 When acute tocolytic effect was compared (that is women 
who had prolongation of pregnancy more than 48 hours) it was 
90%, in group I and 72% in group II.  
16. Neonatal outcome and Neonatal morbidity:  
 When birth weight of babies, compared 58% in group I and 
68% in group II had less than 2.5kg and 42% in group I, 32% in 
group II had birth weight more than 2.5kg. 1 minute mean apgar 
5.02 in group I and 4.4 in group II, 5 minutes mean apgar was 6.38 
in group I and 5.8 in group II. New born ward admissions were 
32% in group II whereas in group I it was only 14%.  
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CONCLUSION  
 
 When compared with nitroglycerin, nifedipine is found to be 
absolutely safe and successful in achieving complete tocolysis.  
 Nifedipine is not only good in acute tocolysis but also very 
effective in prolonging the pregnancy more than 28 days, when in 
comparison with nitroglycerin.  
 When side effects are compared, nifedipine has minimal side 
effects. Neonatal outcome was good with nifedipine, because it 
had better apgar and less morbidity in neonates.   
 To conclude, oral nifedipine has a very good role to play in 
the treatment of acute tocolysis and for prolongation of pregnancy. 
So it can be considered as the  first line drug of choice.  
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PROFORMA 
NAME : AGE : IPNO : UNIT: 
ADDRESS :   PARITY: BOOKED 
/ UNBOOKED: 
   DOA : 
MENSTRUAL HISTORY : REGULAR / IRREGULAR 
LMP  : GESTATIONAL AGE : 
EDD  : 
HISTORY OF PRESENT ILLNESS: 
 H/O LABOUR PAIN 
 H/O DYSURIA 
 H/O STERNOUS WORK / STRESS 
 H/O FIRST TRIMESTER SPOTTING 
 H/O COITUS 
 H/O WHITE DISCHARGE] 
PAST HISTORY 
 PRETERM LABOUR : YES / NO 
 DIABETES MELLITUS  : YES / NO 
 HYPER TENSION : YES / NO 
 HEART DISEASE : YES / NO 
 BRONCHIAL ASTHMA : YES / NO 
 EPILEPSY  : YES / NO 
GENERAL EXAMINATION  
 FEBRILE : YES / NO PR :  
 ANEMIA : YES / NO BP : 
 PEDAL EDEMA : YES / NO RR : 
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 CVS  : 
 RS  : 
ABDOMINAL EXAMINATION 
 UTERUS SIZE IN WEEKS  : 
 UTERINE CONTRACTIONS  :  NUMBER OF CONSTRACTION / DURATION OF 
CONSTRACTION 
 PRESENTING PART  : HEAD / BREECH / OTHERS 
 FETAL HEART RATE  : 
VEGINAL EXAMINATION 
 CERVIX EFFACEMENT  : 25% / 50% / 75% 
 DILATATION  : 1F / 2F / 2CM / 3CM 
 MEMBRANES  : PRESENT / ABSENT 
 PRESENTING PART  : VERTEX / BREECH / OTHERS 
 STATION  : -3 / -2 / -1 / 0 
 PELVIS  : GYNAECOID / OTHER 
 PERVAGINAL  : SHOW / DISCHARGE 
 BISHOP SCOPE  : 
INVESTIGATIONS 
BLOOD URINE: 
 HB : ALBUMIN : 
 SUGAR : SUGAR : 
 UREA : DEPOSITS : 
 S.CREATININE :  
ULTRASONOGRAM 
 SINGLETON / MULTIPLE : 
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 VERTEX / BREECH / OTHERS : 
 GESTATIONAL AGE : 28-30WK/30-32WK / 32-34WK/34-
36WK 
 PLAGENTA  : 
 AFI  : 
 CONGENITAL ANOMALIES : 
 EFW  : 
TREATMENT: 
 INJ. AMPCILLIN  : 500 mg (IV / BD) 
 INJ. BETAMETHASONE : 12 mg / IM / 24 hrs 
APART 
 GROUP 1 NIFEDIPINE : LOADING DOSE 20 – 
30 mg 
    MAINTENANCE DOSE 10 – 
20 mg 
TIME 15min 30min 45min 1 hr 2 hrs 4 hrs 6 hrs 12 hrs 24 hrs 48 hrs 
CONTRACTION           
MPR           
MBP           
FHR           
DOSE           
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 GROUP 2 NITROGLYCERINE : 25 mg PATCH 
TIME 15min 30min 45min 1 hr 2 hrs 4 hrs 6 hrs 12 hrs 24 hrs 48 hrs 
CONTRACTION           
MPR           
MBP           
FHR           
 
SIDE EFFECTS : TACHYCARDIA / HYPOTENSION / 
HEADACHE 
OUTCOME : DELIVERED / DISCHARED 
ELIVERED 
 DATE OF DELIVERY  : 
 MODE OF DELIVERY : LN / FORCEPS / LSCS 
 BABY DETAILS  : WT :  SEX : APGAR:   1 MIN 5 
MIN 
ADMISSION DELIVERY INTERVAL: 
 1 DAY  2DAYS  2-7 DAYS  1-2 WEEKS  2-3WEEKS  3-4 WEEKS       >4 
WEEKS 
DELIVERY AT 
 28 -30 WEEKS  30-32 WEEKS 32-34WEEKS 34-36WEEKS        
>37 WEEKS 
NEONATAL OUTCOME / MORBIDITY 
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1 19 6725 02/07/2011 UB 1 0 0 0 32 HEAD 50% 1CM ‐3 2 2.5hrs NIL 15/3/11 37+ 3 38 2.5 6 8 Nil
2 32 6990 02/10/2011 UB 4 1 1 2 34 HEAD 25% 1CM ‐3 1 2hrs NIL 9/3/2011 37+ 6 27 2.7 6 8 Nil
3 24 7221 15/02/2011 B 1 35 HEAD 75% 3CM ‐1 6 12hrs NAUSEA 20/2/11 35+5 5 2.1 5 6 Nil
4 20 7411 22/02/2011 B 2 1 32 HEAD 50% 1CM ‐3 3 2.5hrs NIL 24/3/11 36+2 30 2.4 5 6 Nil
5 21 7456 22/02/2011 UB 1 32 BREECH 25% <1CM ‐3 2 2hrs NIL 10/4/2011 38+5 47 2.6 6 7 Nil
6 20 8215 03/01/2011 B 1 35 HEAD 50% 1CM ‐2 4 2.5hrs NIL 11/3/2011 36+3 10 2.3 6 7 Nil
7 20 8819 03/04/2011 B 1 32 HEAD 25% 1CM ‐3 1 2hrs NIL 1/4/2011 35+2 23 2.6 5 7 Nil
8 27 8998 20/03/2011 UB 2 1 1 YES 34 HEAD 50% 2CM ‐2 4 6hrs NIL 10/4/2011 37 21 2.7 6 8 Nil
9 25 9202 25/03/2011 B 2 1 1 32 HEAD 25% 1CM ‐3 2 2hrs NIL 22/4/11 36 28 2.4 5 7 Nil
10 19 9314 28/03/2011 UB 1 30 HEAD 25% 1CM ‐2 2 3hrs NIL 27/5/11 38+4 60 2.8 6 8 Nil
11 21 9916 04/02/2011 B 1 28 BREECH 75% 2CM ‐1 6 6hrs NIL 5/4/2011 28+4 3 1.25 2 4 Admission
12 35 10134 04/07/2011 UB 3 2 2 YES 35 HEAD 75% 3CM ‐2 6 6hrs NIL 10/4/2011 35+3 3 2.4 5 6 Nil
13 26 10358 04/12/2011 B 3 1 1 1 30 HEAD 25% <1CM ‐2 2 2hrs NIL 23/5/11 35+6 41 2.6 5 6 Nil
14 24 10755 20/04/2011 B 1 34 HEAD 50% 1CM ‐2 3 4hrs NIL 15/5/11 37+4 25 2.8 6 7 Nil
15 18 10932 24/04/2011 UB 1 32 HEAD 50% 1CM ‐3 2 3hrs NIL 6/6/2011 38+1 43 2.7 6 8 Nil
16 21 11004 29/04/2011 UB 1 34 HEAD 25% <1CM ‐3 2 2hrs NIL 22/5/11 37+2 23 2.6 6 7 Nil
17 24 11138 05/05/2011 UB 2 1 1 34 HEAD 75% 3CM ‐2 6 8hrs NAUSEA 8/5/2011 34+3 3 2.2 5 6 Nil
18 19 11483 14/05/2011 B 1 34 HEAD 50% 2CM ‐3 3 2hrs NIL 31/5/11 36+3 17 2.4 5 6 Nil
19 21 11870 22/05/2011 B 1 30 HEAD 50% 2CM ‐2 3 2hrs NIL 26/6/11 35 35 2.3 5 6 Nil
20 33 11994 28/05/2011 UB 4 2 2 1 32 HEAD 50% 2CM ‐2 3 4hrs NIL 14/6/11 34+3 17 2.1 4 6 Nil
21 19 12125 06/02/2011 B 1 28 BREECH 25% <1CM ‐2 2 2hrs NIL 14/7/2011 34 42 2 5 6 Nil
22 31 12248 06/05/2011 UB 2 1 1 32 HEAD 50% 1CM ‐2 3 3hrs NIL 28/6/11 35+2 23 2.3 5 6 Nil
23 32 12433 06/09/2011 UB 3 2 2 YES 34 HEAD 75% 3CM ‐1 6 8hrs NIL 13/6/11 34+4 4 2.2 4 6 Nil
24 28 12512 06/11/2011 UB 2 1 1 YES 34 HEAD 75% 3CM ‐1 6 6hrs NIL 13/6/11 34+2 2 2 5 6 Nil
25 24 12702 14/06/2011 B 2 1 1 30 HEAD 25% <1CM ‐3 1 2hrs NIL 26/7/11 36 42 2.6 6 7 Nil
MASTER CHART 
GROUP ‐ I
26 18 12818 18/06/2011 UB 1 32 HEAD 75% 3CM ‐2 5 8hrs NIL 24/6/11 32+6 6 1.5 3 4 Admission
27 22 12976 23/06/2011 B 1 30 HEAD 50% 1CM ‐3 3 3hrs NIL 24/7/11 34+3 31 2.3 5 6 Nil
28 27 13028 27/06/2011 UB 4 2 1 1 YES 32 HEAD 75% 2CM ‐2 5 6hrs NIL 3/7/2011 32+6 6 1.8 4 5 Admission
29 23 13159 07/01/2011 B 1 34 HEAD 25% <1CM ‐3 2 2hrs NIL 15/7/11 36 14 2.4 5 6 Nil
30 25 13210 07/03/2011 UB 2 1 1 YES 28 BREECH 25% <1CM ‐2 2 2.5hrs NIL 17/8/11 34+3 45 2.2 5 6 Nil
31 28 13293 07/05/2011 B 3 1 1 1 32 HEAD 75% 3CM ‐1 6 8hrs DIZZINESS        7/7/2011 32+2 2 1.7 4 5 Admission
32 27 13457 07/09/2011 UB 3 1 1 1 34 HEAD 50% 1CM ‐3 3 4hrs NIL 1/8/2011 37+2 23 2.9 6 8 Nil
33 29 13604 07/12/2011 B 4 3 2 30 HEAD 50% 2CM ‐1 4 6hrs NIL 15/7/11 30+3 3 1.4 3 4 Admission
34 18 13836 15/07/2011 B 1 32 HEAD 25% <1CM ‐3 1 2hrs NIL 22/8/11 37+3 38 3 6 8 Nil
35 19 13999 18/07/2011 B 1 34 HEAD 50% 1CM ‐3 3 4hrs NIL 4/8/2011 36+3 17 2.5 5 6 Nil
36 21 14188 20/07/2011 B 1 32 HEAD 25% <1CM ‐3 1 2.5hrs NIL 31/8/11 38 42 3 6 8 Nil
37 28 14514 24/07/2011 UB 2 1 1 34 HEAD 50% 1CM ‐3 2 2hrs NIL 15/8/11 37+1 22 2.9 6 8 Nil
38 30 14980 28/07/2011 UB 3 2 2 YES 32 HEAD 50% 2CM ‐2 4 6hrs NIL 31/7/11 32+3 3 1.6 4 5 Admission
39 19 15012 29/07/2011 UB 1 32 HEAD 25% <1CM ‐2 2 2hrs NIL 29/8/11 36+3 31 2.4 5 6 Nil
40 18 15278 08/02/2011 B 1 34 HEAD 50% 1CM ‐3 2 2hrs NIL 21/8/11 36+5 19 2.7 6 7 Nil
41 34 15312 08/05/2011 UB 4 3 2 YES 36 HEAD 75% 2CM ‐1 6 8hrs NIL 6/8/2011 36+1 1 2.5 5 6 Nil
42 27 15635 08/10/2011 B 1 32 HEAD 75% 3CM ‐1 7 10hrs NIL 12/8/2011 32+2 2 1.3 3 4 Admission
43 25 15923 16/08/2011 UB 1 32 HEAD 25% <1CM ‐3 1 2hrs NIL 21/9/11 37+1 36 2.7 6 8 Nil
44 19 16298 23/08/2011 UB 1 34 HEAD 25% <1CM ‐2 2 2.5hrs NIL 7/9/2011 36+1 15 2.6 5 7 Nil
45 22 16902 09/02/2011 B 3 1 1 1 YES 34 HEAD 50% 1CM ‐2 3 4hrs NIL 7/9/2011 34+5 5 2.2 5 6 Nil
46 19 17120 09/07/2011 UB 1 32 HEAD 25% <1CM ‐3 1 2hrs NIL 1/10/2011 35+3 24 2.4 5 6 Nil
47 26 17805 15/09/2011 UB 2 1 1 YES 36 HEAD 75% 2CM ‐2 6 12hrs NIL 19/9/11 36+4 4 2.4 5 7 Nil
48 21 17998 22/09/2011 UB 3 1 1 1 YES 34 HEAD 75% 3CM ‐1 6 12hrs NIL 24/9/11 34+2 2 1.9 5 6 Nil
49 25 18148 25/09/2011 B 2 1 1 34 HEAD 50% 1CM ‐2 3 4hrs NIL 4/10/2011 35+2 9 2.2 5 6 Nil
50 25 18329 10/01/2011 UB 1 32 HEAD 25% <1CM ‐2 2 2hrs NIL 2/11/2011 36+4 32 2.5 6 7 Nil
51 27 6825 02/09/2011 UB 2 1 34 HEAD 50% 2CM ‐2 4 6hrs NIL 15/2/11 34+6 6 2.2 5 6 Nil
52 21 7175 02/12/2011 B 1 31 HEAD 25% <1CM ‐1 3 4hrs NIL 28/3/11 37+2 44 2.7 6 7 Nil
53 25 7318 18/02/2011 B 2 1 1 34 HEAD 25% <1CM ‐3 1 2hrs NIL 4/3/2011 36 14 2.3 6 7 Nil
54 21 7367 18/02/2011 UB 1 34 HEAD 25% <1CM ‐2 2 4hrs NIL 13/3/11 37+2 23 2.6 5 6 Nil
55 28 7814 25/02/2011 UB 3 1 1 1 34 HEAD 25% 1CM ‐2 2 3hrs NIL 9/3/2011 35+5 12 2.4 5 6 Nil
56 20 8320 03/02/2011 B 1 34 HEAD 25% <1CM ‐2 2 3hrs NIL 13/3/11 35+4 11 2.3 5 6 Nil
57 24 8746 03/07/2011 UB 1 36 HEAD 50% 2CM ‐2 5 6hrs HEADACHE 9/3/2011 36+2 2 2.5 6 7 Nil
58 21 8912 18/03/2011 UB 1 32 BREECH 75% 3CM ‐1 6 12hrs NIL 19/3/11 32+1 1 1.4 4 5 Admission
59 26 9275 27/03/2011 B 1 34 HEAD 50% 1CM ‐2 3 4hrs NIL 10/4/2011 36 14 2.4 6 7 Nil
60 22 10028 04/06/2011 UB 3 1 1 1 YES 32 HEAD 75% 2CM ‐1 5 10hrs NIL 8/4/2011 32+2 2 1.6 3 5 Admission
61 21 10284 04/10/2011 UB 3 2 2 YES 34 HEAD 25% <1CM ‐2 2 2hrs NIL 24/4/11 36 14 2.4 5 6 Nil
62 25 10532 16/04/2011 B 1 35 HEAD 25% <1CM ‐2 2 3hrs NIL 13/5/11 37+3 17 2.8 4 7 Nil
63 23 10855 22/04/2011 B 2 1 1 33 HEAD 25% <1CM ‐2 2 2.5hrs Nil 20/5/11 37 28 2.7 6 7 Nil
64 20 10996 27/04/2011 UB 1 32 HEAD 75% 3CM ‐1 7 10hrs DIZZINESS        27/4/11 32 SAMEDAY 1.3 3 4 Admission
65 20 11228 05/07/2011 B 1 35 HEAD 25% <1CM ‐2 1 2hrs NIL 23/5/11 37+2 16 2.8 5 7 Nil
66 32 11402 05/12/2011 UB 2 1 1 32 HEAD 50% 1CM ‐3 3 6hrs NIL 19/5/11 33 7 2 4 6 Admission
67 26 11785 20/05/2011 UB 1 32 BREECH 50% 1CM ‐2 3 3.5hrs HEADACHE 15/6/11 35+5 26 2.4 5 6 Nil
68 30 11902 24/05/2011 UB 2 1 1 36 HEAD 75% 2CM ‐2 5 12hrs NIL 26/5/11 36+2 2 2.5 4 6 Nil
69 19 12198 06/04/2011 B 1 33 HEAD 50% 1CM ‐3 3 6hrs NIL 14/6/11 34+3 10 2.1 3 5 Admission
70 27 12385 06/07/2011 B 1 32 HEAD 25% <1CM ‐2 2 4hrs NIL 18/6/11 33+4 11 1.8 4 5 Admission
71 26 12584 06/12/2011 UB 2 1 1 YES 34 HEAD 75% 2CM ‐2 5 10hrs HEADACHE 14/6/11 34+2 2 2 3 5 Admission
72 32 12890 20/06/2011 UB 4 3 2 YES 34 HEAD 50% 1CM ‐2 3 6hrs NIL 22/6/11 34+2 2 2.3 5 6 Nil
73 26 12998 25/06/2011 UB 2 1 1 33 HEAD 25% <1CM ‐2 2 4hrs NIL 22/7/11 36+6 27 2.5 5 6 Nil
74 25 13225 07/03/2011 B 1 36 HEAD 50% 1CM ‐2 3 6hrs NIL 10/7/2011 37 7 2.5 4 6 Nil
75 22 13346 07/07/2011 UB 1 34 HEAD 25% <1CM ‐2 2 2.5hrs NIL 19/7/11 35+5 12 2.4 5 6 Nil
GROUP ‐ II
76 28 14112 19/07/2011 UB 2 1 1 YES 28 BREECH 75% 3CM ‐2 6 12hrs TACHYCARDIA 19/7/11 28 SAMEDAY 1.2 3 4 Admission
77 25 14205 21/07/2011 UB 3 1 1 1 32 HEAD 75% 3CM ‐1 6 10hrs Nil 23/7/11 32+2 2 1.5 2 5 Admission
78 23 15073 29/07/2011 UB 2 1 1 30 BREECH 25% 1CM ‐2 2 3hrs NIL 5/9/2011 35+3 38 2.4 5 6 Nil
79 32 15301 08/04/2011 UB 3 2 1 YES 32 HEAD 50% 2CM ‐2 4 4hrs NIL 11/8/2011 33 7 1.8 4 5 Admission
80 22 15467 08/07/2011 UB 3 1 1 1 32 HEAD 25% <1CM ‐2 2 3hrs NIL 29/9/11 35+1 22 2.3 4 6 Nil
81 23 16149 20/08/2011 B 1 30 HEAD 25% 1CM ‐3 2 4hrs NIL 20/9/11 34+3 31 2.2 5 6 Nil
82 24 16423 25/08/2011 B 2 1 32 HEAD 50% 1CM ‐2 3 6hrs NIL 9/9/2011 34+2 16 2.3 5 6 Nil
83 25 16820 09/01/2011 UB 3 2 2 YES 32 HEAD 75% 2CM ‐3 5 10hrs HEADACHE 7/9/2011 32+6 6 1.4 3 4 Admission
84 19 17013 09/04/2011 B 1 30 HEAD 25% <1CM ‐2 2 3hrs NIL 10/10/2011 35+1 36 2.4 5 6 Nil
85 18 17215 09/09/2011 UB 1 32 HEAD 25% <1CM ‐2 2 3.5hrs NIL 7/10/2011 36 28 2.4 5 6 Nil
86 27 17854 16/09/2011 UB 3 1 1 1 32 HEAD 25% <1CM ‐3 2 3hrs NIL 14/10/11 36 28 2.5 5 6 Nil
87 25 18043 23/09/2011 UB 2 1 1 YES 32 HEAD 75% 3CM ‐1 7 12hrs TACHYCARDIA 24/9/11 32+1 1 1.4 3 4 Admission
88 20 18237 28/09/2011 B 1 34 HEAD 75% 1CM ‐3 4 4hrs NIL 4/10/2011 34+6 6 2Kg 5 6 Nil
89 31 18342 10/01/2011 UB 3 2 2 YES 34 HEAD 75% 3CM ‐1 6 10hrs HEADACHE 2/10/2011 34+1 1 1.9 3 5 Admission
90 25 18604 10/09/2011 B 1 32 HEAD 50% 1CM ‐2 2 4hrs NIL 27/10/11 34+4 18 2 2 5 Admission
91 18 18712 10/12/2011 B 1 34 HEAD 25% <1CM ‐3 2 3hrs NIL 3/11/2011 37+1 22 2.9 6 8 Nil
92 31 18854 15/10/2011 UB 4 1 1 2 28 BREECH 75% 3CM ‐1 6 12hrs HEADACHE 17/10/11 28+2 2 1.2 3 4 Admission
93 18 18920 16/10/2011 B 1 36 HEAD 75% 1CM ‐3 4 4hrs NIL 21/10/11 36+5 5 2.4 5 6 Nil
94 19 19078 19/10/2011 UB 1 34 HEAD 50% 1CM ‐3 3 8hrs NIL 4/11/2011 36+2 16 2.6 5 7 Nil
95 30 19134 21/10/2011 UB 3 1 1 1 30 HEAD 75% 3CM ‐1 6 8hrs DIZZINESS        23/10/11 30+2 2 1.3 3 4 Admission
96 23 19198 23/10/2011 B 1 34 HEAD 25% <1CM ‐3 3 6hrs NIL 11/11/2011 36+5 19 2.5 5 6 Nil
97 29 19251 25/10/2011 UB 3 1 1 1 33 HEAD 50% 1CM ‐2 3 6hrs NIL 15/11/11 37 21 2.8 6 7 Nil
98 19 19328 28/10/2011 B 2 1 1 34 HEAD 25% <1CM ‐3 2 5hrs NIL 15/11/11 36+4 18 2.5 5 6 Nil
99 24 19382 29/10/2011 UB 2 1 1 34 HEAD 50% 1CM ‐2 3 5hrs NIL 7/11/2011 35+2 9 2.4 5 6 Nil
100 19 19550 11/02/2011 UB 1 36 HEAD 75% 2CM ‐2 5 10hrs HEADACHE 4/11/2011 36+2 2 2.5 5 6 Nil
